GlassScriptPhysician profile
Leslie A Masood
NPI 1396951240
$30,124.92
in general payments reported to CMS, 2019-2025
57 companies · $3,185 in 2025
The $3,185 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $1,504 · 2021: $12K · 2022: $5,354 · 2023: $3,341 · 2024: $3,675 · 2025: $3,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,128.45 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $6,897.62 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $3,913.27 | 2019-2025 | |
| Abbvie INC. | $3,179.96 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,692.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $1,525.44 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Lilly USA, LLC | $1,040.38 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $849.80 | 2023-2025 | |
| Amgen INC. | $769.80 | 2019-2024 | Aimovig |
| Celgene Corporation | $761.00 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $741.67 | 2019-2024 | Qelbree |
| Biogen, INC. | $672.93 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Sk Life Science, INC. | $559.01 | 2020-2025 | |
| Eisai INC. | $467.19 | 2021-2025 | |
| Lundbeck LLC | $439.51 | 2020-2025 | Vyepti |
| Mdd US Operations, LLC | $424.48 | 2023-2025 | Apokyn, Gocovri, Qelbree |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $402.12 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $324.25 | 2020-2025 | Onzetra Xsail, Contrave |
| Upsher-Smith Laboratories LLC | $315.12 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $292.14 | 2019-2025 | Crexont, Brekiya, Rytary |
| Janssen Pharmaceuticals, INC | $281.99 | 2021-2023 | Ponvory |
| Acadia Pharmaceuticals INC | $254.16 | 2019-2024 | Nuplazid, Daybue |
| Vanda Pharmaceuticals INC. | $247.42 | 2024-2025 | Ponvory |
| Banner Life Sciences, LLC | $229.26 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $217.48 | 2020-2022 | |
| Tonix Medicines, INC. | $206.33 | 2024-2025 | Zembrace Symtouch |
| Sunovion Pharmaceuticals INC. | $202.75 | 2020-2022 | |
| Axsome Therapeutics, INC. | $171.60 | 2025 | Symbravo |
| Argenx US, INC. | $169.73 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Acorda Therapeutics, INC | $167.14 | 2020-2024 | Inbrija, Ampyra |
| Ipsen Biopharmaceuticals, INC | $162.30 | 2020-2025 | Dysport |
| Zyla Life Sciences, INC. | $151.05 | 2019-2020 | |
| Livanova USA, INC. | $134.80 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Idorsia Pharmaceuticals US INC | $114.46 | 2023-2025 | Quviviq, Quviviq |
| Alnylam Pharmaceuticals INC. | $93.54 | 2019-2021 | |
| Ucb, INC. | $90.33 | 2019-2021 | |
| Neuronetics, INC. | $80.58 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $72.67 | 2024-2025 | Wainua |
| Cycle Pharmaceuticals INC | $71.14 | 2025 | Bafiertam |
| Emd Serono, INC. | $69.08 | 2019-2020 | |
| Abbott Laboratories | $63.65 | 2025 | Infinity |
| Avion Pharmaceuticals | $63.34 | 2022 | |
| Genentech USA, INC. | $59.43 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Scilex Pharmaceuticals INC. | $59.21 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $53.46 | 2022 | |
| Boston Scientific Corporation | $43.11 | 2023 | |
| Impel Pharmaceuticals INC. | $37.10 | 2023 | Trudhesa |
| Assertio Therapeutics, INC. | $33.86 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $33.84 | 2019 | |
| Novo Nordisk INC | $32.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.64 | 2024 | Nuedexta |
| Impel Pharmaceuticals LLC | $27.04 | 2025 | Trudhesa |
| Promius Pharma LLC | $26.33 | 2019 | |
| Tanabe Pharma America, INC. | $26.07 | 2025 | Radicava |
| Takeda Pharmaceuticals U.S.A., INC. | $22.83 | 2022 | |
| Akcea Therapeutics, INC. | $22.56 | 2019 | |
| Almatica Pharma LLC | $22.01 | 2021 | |
| Grifols USA, LLC | $15.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.